Please ensure Javascript is enabled for purposes of website accessibility

Why Eli Lilly Stock Is Soaring Today

By Keith Speights – Jun 24, 2021 at 10:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's promising Alzheimer's disease drug won FDA Breakthrough Therapy designation.

What happened

Shares of Eli Lilly (LLY 0.19%) were soaring 7.8% higher at 11:05 a.m. EDT on Thursday. The big gain came after the drugmaker announced that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Therapy designation to Lilly's experimental Alzheimer's disease drug donanemab. Lilly also said that it plans to file for accelerated FDA approval of the drug later this year.

So what

Breakthrough Therapy designation allows for an expedited review of drugs that target serious conditions. This designation can be given when "preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s)."

Jigsaw puzzle shaped like a human brain with one missing piece to the side.

Image source: Getty Images.

Lilly chief scientific officer Dan Skovronsky stated in April that the company wouldn't seek accelerated approval based on phase 2 results for donanemab. Now the big drugmaker is moving forward. What changed? Biogen's (BIIB -1.42%) FDA approval for Alzheimer's disease drug Aduhelm.

In March, Lilly reported promising data from a phase 2 study of donanemab. The drug showed significant slowing of cognitive decline on a commonly used scale compared to placebo. With Biogen winning FDA approval for Aduhelm earlier this month, many expected Lilly to push for an accelerated approval pathway for its Alzheimer's disease candidate.

Now what

Investors have good reason to cheer today's news from Lilly. The big pharma stock could have another positive catalyst on the way as well. An FDA approval decision for Olumiant in treating moderate to severe atopic dermatitis is expected in the early part of the third quarter of this year. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$311.46 (0.19%) $0.59
Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$197.78 (-1.42%) $-2.84

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.